Pigmented lesion is a skin disease usually referred to as melanocytic proliferations. Pigmented lesions are brown, black or blue in color, due to melanin, blood, or exogenous pigment. Spreading or growing lesions, pigmented lesions on exposed skin can be a symptom of skin cancer. Pigmented lesion are classified as non-melanocytic lesions and melanocytic lesions, and further classified as benign and malignant. Malignant lesion is a tissue, which appears abnormal under microscopic examination, and is more likely be cancer tissue. Therefore, removal of premalignant lesion reduces proliferation and occurrence of malignant skin diseases. Early diagnosis and complete removal of lesions can prevent occurrence of all types of skin cancers. Factors for pigment lesion are natural and environmental that includes, photodamage i.e. constant exposure to ultraviolet (UV) radiation, which leads to skin problems, early skin aging.
Almost all age group population are susceptible to pigment lesion. There are wide range of laser treatments available for pigmented lesion such as ErYAG, MedLite laser, which are effective and relatively affordable.
Increasing laser systems for treatment of pigmented lesion favors growth of the pigmented lesion treatment market
Manufacturers are focusing on innovation to deliver new and advanced treatment options for pigmented lesion. For instance, in 2014, Syneron Medical Ltd. launched PicoWay picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam for pigmented lesion treatment and tattoo removal. PicoWay is a dual wavelength device, with 532nm and 1064nm wavelength. Furthermore, in 2014, Lutronic Corporation launched Lutronic XT Q-Switched, frequency doubled Nd:YAG laser, known as the Spectra XT, the system includes several treatment application such as pigmented lesion, tattoo removal, melisma, pore-size reduction, and skin-rejuvenation.
Cutera, Inc. introduced two new laser systems at the 72nd American Academy of Dermatology conference, 2014 in the U.S. Both the lasers, named excel HR and Enlighten, are targeted for hair removal, tattoo removal, and benign pigmented lesion. In 2016, Cynosure received FDA clearance to market PicoSure Energy delivery system for tattoos and pigmented lesions.
Pigmented Lesion Treatment Market taxonomy
By Laser Type:
- Fractional CO2
By Indication Type:
- Non-melanocytic lesions
- Benign neoplasms
- Malignant neoplasms
- Melanocytic lesions
By End User
- Skin Clinics
Asia Pacific is expected to show significant growth in the pigmented lesion treatment market over the forecast period
On the basis of region, the global pigmented lesion treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account for the largest share, followed by Europe and Asia Pacific, respectively over the forecast period. Growth of the pigmented lesion treatment market in North America is driven by factors such as increasing aesthetic awareness and growing prevalence of pigmented lesion. According to Skin Cancer Foundation, yearly over 5.4 million cases of non-melanoma skin cancer are reported in the U.S. and over 3.3 million people receive treatment, which in turn favors growth of pigmented lesion treatment market in North America. Pigmented lesion treatment market in Asia Pacific is expected to witness high growth owing to factors such as increasing government support for treatment of lesion. For instance, the New South Wales (NSW) Government selected 12 innovative tech start-ups to exhibit at CeBIT Australia. Among these companies, Dermaspec, which is a high-quality, color calibrated low-cost camera for dermatoscopic imaging of pigmented skin lesions. at a modest cost, which in turn will favor the growth of pigmented lesion market in Asia Pacific region.
Furthermore, the growth of Asia Pacific is supported by the Syneron Medicals Ltd. revenue of 2016 as the North America product revenue of the Syneron was up approximately 20% Y-o-Y, Asia-Pacific product revenue was up approximately 25% Y-o-Y, and EMEA region product revenue was up approximately 9% Y-o-Y.
Increasing competition in the product space is driving innovation in treatment systems, which is expected to fuel growth of the global pigmented lesion treatment market
In September 2017, Fotona — a company based in the U.S. and Europe — received FDA clearance for its new StarWalker MaQX Q-Switched laser system for treating tattoos, pigmented and vascular lesions, acne and scar revision, and even for permanent hair reduction. Such constant product approval increases the competition between key market players in pigmented lesion treatment market.
Key players operating in the global market of pigmented lesion treatment market include Lutronic Corporation, Fotona d.d., Alma Lasers, Ltd., EL.En. S.p.A., Solta Medical Inc., Cynosure, Inc., Syneron Medical Ltd., Sciton, Inc., Cutera Inc., Lumenis Ltd., Strata Skin Sciences, Inc., and Lynton Lasers Ltd.